A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy.

被引：0
|
作者：
Plimack, Elizabeth R. [1 ]
Campbell, Kerry [1 ]
Issa, Jean-Pierre J. [2 ]
Hahn, Noah M. [3 ]
Quinn, David I. [4 ]
Jang, Hyo Sik [5 ]
Hostetter, Galen [5 ]
Nichols, Peter W. [4 ]
Chung, Woonbok [2 ]
Madzo, Jozef [2 ]
Ohtani, Hitoshi [5 ]
Shen, Hui [5 ]
Hinoue, Toshinori [5 ]
Baylin, Stephen B. [3 ]
Jones, Peter A. [5 ]
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Coriell Inst Med Res, Camden, NJ USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Van Andel Res Inst, Grand Rapids, MI USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT121
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
    Jang, H. Josh
    Hostetter, Galen
    Macfarlane, Alexander W.
    Madaj, Zachary
    Ross, Eric A.
    Hinoue, Toshinori
    Kulchycki, Justin R.
    Burgos, Ryan S.
    Tafseer, Mahvish
    Alpaugh, R. Katherine
    Schwebel, Candice L.
    Kokate, Rutika
    Geynisman, Daniel M.
    Zibelman, Matthew R.
    Ghatalia, Pooja
    Nichols, Peter W.
    Chung, Woonbok
    Madzo, Jozef
    Hahn, Noah M.
    Quinn, David I.
    Issa, Jean-Pierre J.
    Topper, Michael J.
    Baylin, Stephen B.
    Shen, Hui
    Campbell, Kerry S.
    Jones, Peter A.
    Plimack, Elizabeth R.
    CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2052 - 2065
  • [2] Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT).
    Doshi, Gurjyot K.
    Vogelzang, Nicholas J.
    Richards, Donald A.
    Chong, Daniel
    Shaffer, David R.
    Nordquist, Luke T.
    Picus, Joel
    Alvarez, Delia
    Der-Torossian, Hirak
    Christensen, James
    Yorio, Jeffrey Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
    Girardi, Daniel M.
    Niglio, Scot A.
    Mortazavi, Amir
    Nadal, Rosa
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Hadi
    Redd, Bernadette
    Steinberg, Seth M.
    Costello, Rene
    Chan, Keith S.
    Lee, Min-Jung
    Lee, Sunmin
    Yu, Yunkai
    Gurram, Sandeep
    Chalfin, Heather J.
    Valera, Vladimir
    Figg, William D.
    Merino, Maria
    Toubaji, Antoun
    Streicher, Howard
    Wright, John J.
    Sharon, Elad
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Cao, Liang
    Trepel, Jane B.
    Apolo, Andrea B.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1353 - 1362
  • [4] Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
    Girardi, Daniel da Motta
    Niglio, Scot Anthony
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma
    Galsky, Matthew D.
    Hahn, Noah M.
    Wong, Bryan
    Lee, Karen M.
    Argiriadi, Pamela
    Albany, Costantine
    Gimpel-Tetra, Kiev
    Lowe, Nancy
    Shahin, Mohamed
    Patel, Vaibhav
    Tsao, Che-Kai
    Oh, William K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1259 - 1265
  • [7] Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D. Galsky
    Noah M. Hahn
    Bryan Wong
    Karen M. Lee
    Pamela Argiriadi
    Costantine Albany
    Kiev Gimpel-Tetra
    Nancy Lowe
    Mohamed Shahin
    Vaibhav Patel
    Che-Kai Tsao
    William K. Oh
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1259 - 1265
  • [8] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    McGregor, Bradley Alexander
    Green, Marjorie C.
    Mohamed, Nehal
    Chang, Pei-Yun
    Powles, Thomas
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).
    Maia, Manuel C.
    Agarwal, Neeraj
    McGregor, Bradley Alexander
    Vaishampayan, Ulka N.
    Choueiri, Toni K.
    Green, Marjorie C.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Powles, Thomas
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [10] Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma
    Tsao, Che-Kai
    Agarwal, Neeraj
    Apolo, Andrea Borghese
    Lee, Karen M.
    Godbold, James H.
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345